Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of De...

Nytt kapital för utveckling av nasalt covid-vaccin mot omikron

Forskningsbolaget ISR Holding planerar att ta in 400 miljoner kronor för att snabba på sina utvecklingsprojekt kring HIV, hepatit, immunonkologi och vaccin mot ...

Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell

Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Mich...

Precision and accuracy in liquid handling

How to evaluate and optimize liquid handling performance

On the hunt for high throughput diagnostics

Global diagnostics companies and laboratories are in a race against time to adapt testing capacity to current demand. Due to the global COVID 19 pandemic, the d...

Suing the company – for NOT developing a new HIV drug

Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...

Neutronmöte i Lund samlar hundratals toppforskare

För första gången hålls en konferens knuten till den nya forskningsanläggningen ESS i Lund. Det är Institut Laue-langevin, ILL, i Frankrike och European Spallat...

New diagnostic test soon ready for the market

Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation

A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure that new medicines will be available for all citizens in Europe, writes Marie Gårdmark...

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients...

Så mycket väntas lecanemab sälja globalt

Försäljningen av Leqembi (lecanemab), som nyligen fick ett accelererat USA-godkännande som behandling mot Alzheimers sjukdom, väntas globalt uppgå till sju milj...

New issue of Life Science Sweden!

The international issue of Life Science Sweden has been sent to press.

Trends and overview: ELRIG "Robotics and Automation"

Laboratories on the way to end-to-end automation: Robotics, artificial intelligence and automation technology boosted by pandemic

Ny ordförande för Atlas Antibodies

Åsa Riisberg, styrelseproffs och tidigare partner i EQT, tar över ordförandeklubban i Atlas Antibodies.

Save time and money !

Festo Digital engineering tools helps you to calculate the most cost and efficient solution for your application for free

Ready-to-install solutions for the lab-on-a-chip

Design for manufacturing lab-on-a-chip devices Reducing time-to-market together

Neanderthal genes and Nobel Prize in a popular lecture at Bioscience

An inherited gene variant from our ”evolutionary cousins” – the extinct Neanderthals – may affect how our bodies break down certain drugs. “It’s only a matter o...

Column: ”Cheating with pea flowers and does it matter whether you are right?”

Is it possible to forgive shortcuts or outright cheating in science - if it turns out that the researcher was ultimately right? Anna Törner discuss this topic in a column.

Krönika: Can regulators keep up with innovation?

New technology has increased the understanding of disease mechanisms and enabled approval of products targeting small but specific patient populations; sometime...

High hopes for future partnering - the solution for struggling fairs

Business fairs are struggling but the concept of partnering is hotter than ever. By using social media, participants can prepare themselves for the perfect meeting.

“Everyone is screaming for talent”

Attracting talent is one of the life science industry’s major future challenges, which was one of the conclusions of the panel discussion that ended the New Hor...

Young, bright and committed to labtech

, becoming the new CEO of Swedish Labtech.

Life Science-podden: The perfect moment for an IPO

When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?

Academia - a strong player on the lab market

While the industry was short of money during the financial crisis, government incentives were in full swing in Sweden during 2009. - Our sales to academia incre...